About CHINA ASSET MANAGEMENT (HK) CHINAAMC HANG SENG BIOTECH ETF HKD

3069 invests in stocks. The fund's major sectors are Health Technology, with 86.22% stocks, and Consumer Non-Durables, with 4.47% of the basket. The assets are mostly located in the Asia region.

3069 top holdings are Innovent Biologics, Inc. and BeOne Medicines Ltd., occupying 9.57% and 9.12% of the portfolio correspondingly.

3069 last dividends amounted to 0.06 HKD. The year before, the issuer paid 0.03 HKD in dividends, which shows a 50.00% increase.

3069 assets under management is ‪502.44 M‬ HKD. It's risen 62.38% over the last month.

3069 fund flows account for ‪−456.68 M‬ HKD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

3069 shares are issued by CITIC Securities Co., Ltd. under the brand ChinaAMC. The ETF was launched on Mar 18, 2021, and its management style is Passive.

3069 expense ratio is 0.71% meaning you'd have to pay 0.71% of your investment to help manage the fund.

3069 follows the Hang Seng Biotech Index - HKD - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

3069 invests in stocks.

3069 price has risen by 13.01% over the last month, and its yearly performance shows a 58.19% increase. See more dynamics on 3069 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 11.34% over the last month, showed a 22.86% increase in three-month performance and has increased by 60.57% in a year.